Key Insights into the Diagnosis and Treatment of Inflammatory Bowel Disease (IBD)

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2018 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from January 15, 2019 to January 31, 2020

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
Celgene and Takeda Pharmaceuticals

According to the Crohn’s and Colitis Foundation of America, there are as many as 70,000 new cases of Inflammatory bowel disease (IBD) diagnosed in a year. This chronic, frequently progressive condition affects approximately 1.6 million people in the United States. IBD often strikes patients at a young age, thereby making the management of this disease a lifetime endeavor. The first step for IBD treatment is aminosalicylates, which are useful for treating flares of IBD and for maintaining remission. There are also the uses of antibiotics that are used to treat bacterial infections that may result from abscesses or fistulas. While corticosteroids, rapid-acting anti-inflammatory agents, are indicated for acute flares of disease, they have no role in the maintenance of remission. Immunomodulators have a slower onset of action and work to reduce patients’ overactive immune system but unlike corticosteroids, they can be used as a long-term treatment. And the final way to treat IBD is with biologics, which are proteins that stop certain molecules in the body from causing inflammation in the GI tract. These are usually prescribed to those living with moderate to severe cases of IBD who haven’t responded to other types of treatment. This presentation will provide clinical data and evidence needed to help optimize the current treatments and educate clinicians and healthcare professionals on the novel biologics.

Upon completion of this activity, participants will be able to:

  • Analyze the efficacy and safety profiles of biologic therapies for inflammatory bowel disease (IBD) that act through different mechanisms

  • Evaluate the role of emerging non-biologics for patients with IBD

  • Explore the best approaches for diagnostic modalities and assessment tools that can improve the early diagnosis of IBD

  • Identify the impact of biologic therapeutic agents on infection risks and how to effectively minimize those risks

  • Discuss strategies to treat and manage patients with moderate-to-severe IBD based on risk stratification by using personalized treatment targets

  • Assess strategies to improve preventive care in IBD patients within a managed care and health system

Faculty: Siddharth Singh, MD, MS
Assistant Professor of Medicine
University of California San Diego


Dr. Singh serves on an advisory board for AbbVie and AMAG Pharmaceuticals. He serves as a consultant for Pfizer. He has received grant/research support from AbbVie and Pfizer. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by educational grants from
Celgene and Takeda Pharmaceuticals

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue